Expert Opinion on Biological Therapy

Papers
(The H4-Index of Expert Opinion on Biological Therapy is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm cli107
Antibody drug conjugates for glioblastoma: current progress towards clinical use53
Aflibercept biosimilars – so near, yet so far52
Microbiota transplantation and administration of live biotherapeutic products for the treatment of dysbiosis-associated diseases51
A comprehensive overview on the anti-inflammatory, antitumor, and ferroptosis functions of bromelain: an emerging cysteine protease45
The endosomal-lysosomal system in ADC design and cancer therapy39
Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?39
Biosimilars and access to biologic therapy in immune-mediated diseases37
Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males37
Management of chronic recurrent multifocal osteomyelitis: review and update on the treatment protocol33
A review of bridging clinical studies between different presentations of biological products approved by the United States Food and Drug Administration (US FDA)31
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma30
What’s new in the use of antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) DNA cross-linkers for cancer therapy?30
Development and Clinical Translation Considerations for the Next Wave of Gene Modified Hematopoietic Stem and Progenitor Cells Therapies30
Correction30
Optimization of radiation target volume for locally advanced esophageal cancer in the immunotherapy era28
Long-acting delivery and therapies for neovascular age-related macular degeneration27
Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors25
Biologics in severe asthma: Outcomes in clinical trials-Similarities and differences24
Signaling new therapeutic opportunities: cytokines in prostate cancer23
Development of multi-epitope vaccine constructs for non-small cell lung cancer (NSCLC) against USA human leukocyte antigen background: an immunoinformatic approach toward future vaccine designing21
Correction21
Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway21
Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden21
0.068084955215454